Navigation Links
Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand

- Neptune Technologies & Bioressources Inc. enters into an exclusive distribution agreement with AZPA International Inc. for Australia and New

Zealand -

LAVAL, QC, Dec. 19 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has entered into an exclusive distribution agreement with AZPA International Inc. ("AZPA International") for Australia and New Zealand. AZPA International, a leading supplier to the pharmaceutical, nutritional health and cosmetics industries, has also acquired non-exclusive rights to commercialize Neptune's products in Southeast Asia and Hong Kong.

The nationwide product launch of Neptune Krill Oil (NKO(R)) in Australia and New Zealand, claiming cardiovascular and joint health benefits, is scheduled for February 2008. A pre-requisite for commercializing NKO(R) in Australia hence New Zealand is obtaining approval as a complementary medicine from the Therapeutic Goods Administration (TGA) which notification Neptune has recently announced.

AZPA International joined forces for the commercialization and distribution of NKO(R) with PharmaLink Pte. Ltd. ("PharmaLink"), a leading provider of complementary and over-the-counter medicines and a leader in healthcare sales and marketing in the Asia-Pacific region. PharmaLink will be reaching the market through its primary care team, its pharmacy/ OTC team and its specialist/ allied health team.

"It is estimated that 74% of the Australian population has used complementary medicine in the previous twelve months and usage rates are expected to rise,(1)" said Thierry Houillon, Vice President of Nutraceuticals of Neptune. "An estimated annual increase of 18% has been reported for the complementary medicine market in Australia.(2) We are looking forward to working with AZPA International and PharmaLink benefiting from this trend and making NKO(R) a household name in Australia and New Zealand," he added.

PharmaLink, in collaboration with AZPA International, will also prepare a comprehensive marketing campaign, including medical conventions, tradeshows, and extensive press and mass media coverage. Selected consumers will be taking NKO(R) for a period of three months and will subsequently be reporting on radio & TV talk shows about their experience with NKO(R).

In addition, AZPA International will be working with Lipa Pharmaceuticals, Australia's leading contract manufacturer to the nutritional and pharmaceutical industries, which makes products in key growth areas of complementary and alternative medicines, over-the-counter (OTC) and prescription pharmaceuticals.

1. Source: Cardinal Health. Vitamin, Mineral, Herbal and Nutritional

Supplements, 4 October 2005

2. Source: Complementary Healthcare Council communication, 13 September


About Neptune Technologies & Bioressources Inc.

Neptune develops proprietary health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, the Company is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neptune continues to strongly support its strategic development plan to form partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. Neptune has recently signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, paving its entrance into the global functional food market. According to its business strategy, negotiations with pharmaceutical companies with the objective of entering the pharmaceutical market by licensing rights are ongoing.

NASDAQ and TSX venture exchange does not accept responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted
2. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
3. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
4. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):